AMENDMENTS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1-13. (Canceled)

14. (Currently amended) A method for decreasing cellular replication in a GnRH-receptor positive tumor in a subject selected from the group consisting of a malignant tumor originating in one or more of the brain, the nervous system, or meninges of the brain; Ewing sarcoma; Kaposis sarcoma; and malignant melanoma, said method comprising administering to said subject a replication decreasing amount of one or more of a GnRH agonist or GnRH antagonist, said GnRH agonist or antagonist being a GnRH analogue selected from the group leuprorelin, triptorelin, buserelin, goserelin, Synarela®, Cetrorelix®, Antarelix®, Antide®, Ramorelix® or pharmacologically acceptable salts thereof, so as to decrease cellular replication in the GnRH-receptor positive tumor.

15. (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is Kaposi sarcoma

16. (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is Glioblastoma multiforme, medulloblastoma, pinealoma, neuroblastoma, craniopharyngeoma, meningeoma, chordoma, Ewing sarcoma, malignant melanoma, or Kaposi sarcoma.

17. (Currently amended) The method according to claim 14, wherein the GnRH ~~agonists~~agonist or GnRH ~~antagonists are~~antagonist analogue used in combination with a cytotoxic substance.

18. (Previously presented) The method of claim 14 wherein the GnRH-receptor positive tumor is malignant melanoma.

19. (Currently amended) A method for decreasing cellular replication in a GnRH-receptor positive tumor in a subject selected from the group consisting of a malignant tumor originating in one or more of the brain, the nervous system, or meninges of the brain; Ewing sarcoma; Kaposis sarcoma; and malignant melanoma, said method comprising administering to said subject a replication decreasing amount of a GnRH agonist or GnRH antagonist coupled to a cytotoxic substance, said GnRH agonist or GnRH antagonist being a GnRH analogue selected from the group leuprorelin, triptorelin, buserelin, goserelin, nafarelin, Cetrorelix®, Antarelix®, Antide®, Ramorelix® or pharmacologically acceptable salts thereof, so as to decrease cellular replication in the GnRH-receptor positive tumor.

20. (Previously presented) The method of claim 19 wherein the GnRH-receptor positive tumor is malignant melanoma.